Skip to main content


Following is a selection of peer-reviewed journal articles for which I provided professional medical writing support.

In addition to manuscripts, I have written many posters and abstracts, and I am happy to support congress activities.

RWE and Economic Analyses

Schneider S, Blick G, Burke C, et al. Two-drug regimens dolutegravir/lamivudine and dolutegravir/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study. Infect Dis Ther. 2024;13:891-906.

Benson P, Kuretski J, Donovan C, et al. Real-world effectiveness of dolutegravir/lamivudine in people with HIV-1 in test-and-treat settings or with high baseline viral loads: TANDEM study subgroup analyses. Infect Dis Ther. 2024;13:875-889. 

Afzali A, Lukanova R, Hennessy F, et al. Unmet needs in real-world advanced therapy-naïve and -experienced patients with moderately to severely active ulcerative colitis in the United States. Adv Ther. 2023;40:4321-4338.

Czarnogorski M, Garris CP, Dalessandro M, et al. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE). J Int AIDS Soc. 2022;25:e26003.

Neuberger EE, To TM, Seetasith A, Arndorfer SM, Wallick CJ. Antiviral use and health care use among US patients with rheumatoid arthritis and influenza in three influenza seasons, 2016-2019. ACR Open Rheumatol. 2022;4:631-639.

Berling M, Chaudhary MA, Yuan Y, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. J Med Econ. 2022;25:703-711.

Grigoryan L, Mulgirigama A, Powell M, Schmiemann G. The emotional impact of urinary tract infections in women: a qualitative analysis. BMC Womens Health. 2022;22:182.

Chen G, Pedarla V, Null KD, Cazzetta SE, Khan QR, Schwartz DA. Health care costs and resource utilization among patients with Crohn's disease with and without perianal fistula. Inflamm Bowel Dis. 2021 Sep 15:izab198.

Sanon Aigbogun M, Oberdhan D, Doane MJ, et al. Disconnect in assessments of autosomal dominant polycystic kidney disease burden between patients and physicians: a survey study. Int J Nephrol Renovasc Dis. 2021;14:105-115.

Waltrip RW II, Mahler N, Ahsan A, Herbert LB. Effect of health care providers' focused discussion and proactive education about relapse management on patient reporting of multiple sclerosis relapse. Int J MS Care. 2021;23:151-156.

Wong W, Wu N, Gupta R, Mansfield AS. Utilization trends and factors associated with ROS1 testing among patients with advanced non-small-cell lung cancer in US community practices. Clin Lung Cancer. 2020:S1525-7304(20)30213-8.


Ratziu V, Harrison SA, Hajji Y, et al. NIS2+™ as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. J Hepatol. 2024;80:209-219. 

Ogasawara A, Ide R, Inoue S, Teng R, Kawaguchi A. Effect of hepatic and renal impairment on the pharmacokinetics of dersimelagon (MT-7117), an oral melanocortin-1 receptor agonist. Clin Pharmacol Drug Dev. 2024 May 15. Epub ahead of print. 

Stathis A, Tolcher AW, Wang JS, et al. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Invest New Drugs. 2023;41:380-390.

Harrison SA, Ratziu V, Magnanensi J, et al. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol. 2023;79:758-767.

Tsuda M, Ogawa K, Endou T, Goto T, Ogasawara Y, Ogasawara A. Absorption, metabolism, and excretion of [14C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers. Pharmacol Res Perspect. 2023;11:e01084. 

Mutch P, Bashir M, Jung B, Yi P, Iverson M. Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants. Xenobiotica. 2022;52:707-717.

Landry I, Hall N, Aluri J, et al. Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users. J Clin Psychopharmacol. 2022;42:365-373.

Dash A, Pinner K, Inoue Y, et al. Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. Sleep Med X. 2022;4:100044.

Bilder DA, Arnold GL, Dimmock D, et al. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria. Am J Med Genet A. 2022;188:768-778.

Statland JM, Campbell C, Desai U, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022;66:50-62.

Roth T, Rosenberg R, Morin CM, et al. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Med. 2022;90:249-257.

Alexis AF, Desai SR, Han G, Jacobson A. Fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in patients with skin of color. J Drugs Dermatol. 2021;20:744.

Agbo F, Isaacson SH, Gil R, et al. Pharmacokinetics and comparative bioavailability of apomorphine sublingual film and subcutaneous apomorphine formulations in patients with Parkinson's disease and "OFF" episodes: results of a randomized, three-way crossover, open-label study. Neurol Ther. 2021;10:693-709.

Tanghetti EA, Bhatia N, Drew S, Jacobson A. Fixed-combination halobetasol propionate/tazarotene lotion for psoriasis in patients with 3%-5% affected body surface area. J Drugs Dermatol. 2021;20:829-836.

Cheng JY, Moline M, Zammit GK, Filippov G, Bsharat M, Hall N. Respiratory safety of lemborexant in healthy subjects: a single-dose, randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2021;41:449-457.

Agbo F, Crass RL, Chiu YY, Chapel S, Galluppi G, Blum D, Navia B. Population pharmacokinetic analysis of apomorphine sublingual film and subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease. Clin Transl Sci2021;14:1464-1475.

Vermeire S, Chiorean M, Panés J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021:jjab016.

Moline M, Zammit G, Yardley J, Pinner K, Kumar D, Perdomo C, Cheng JY. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med. 2021;133:71-81.

Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A. Malignancy rates in brodalumab clinical studies for psoriasis. Am J Clin Dermatol. 2020;21:421-430.

Tauber J. A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea. 2020;39:403-407.

Cheng JY, Filippov G, Moline M, Zammit GK, Bsharat M, Hall N. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study. J Sleep Res. 2020:e13021.

Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183:1037-1048.

Pepose JS, Qazi MA, Devries DK. Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity. Clin Ophthalmol. 2019;13:571-579.

Borin MT, Lo A, Barnes CN, Pendyala S, Bourdet DL. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. Int J Chron Obstruct Pulmon Dis. 2019;14:2305-2318.

Guerci B, Trautmann ME, Lin T, Hardy E, Mudaliar SRD. Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study. Diabetes Obes Metab. 2019;21:1049-1053.

Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol. 2019;9:388-395.

Roca-Ferrer J, Pujols L, Pérez-González M, Alobid I, Callejas B, Vicens-Artés S, Fuentes M, Valero A, Picado C, Castor D, Nguyen D, Mullol J. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy Asthma Clin Immunol. 2018;14:86.

Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P; DURATION-NEO-2 study investigators. Efficacy and safety of auto injected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19:979-988.

Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49 years. Vaccine. 2017;35:1254-1258.

Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19:1276-1288.

McLean HQ, Caspard H, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine. 2017;35:2685-2693.

Tauber J, Karpecki P, Latkany R, et al; OPUS-2 Investigators. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122:2423-2431.

Peyrani P, Wiemken TL, Kelley R, et al; IMPACT-HAP Study Group. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014;18:R118.

Puzniak LA, Capitano B, Biswas P, Lodise TP. Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: a pooled data analysis. Diagn Microbiol Infect Dis. 2014;78:295-301.

Quartin AA, Scerpella EG, Puttagunta S, Kett DH. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis. 2013;13:561.

Dahlin LB, Bainbridge C, Szczypa PP, Cappelleri JC, Guérin D, Gerber RA. Current trends in the surgical management of Dupuytren’s disease in Europe: the surgeon’s perspective. Eur Orthop Traumatol. 2012;3:25-30.

Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. J Antimicrob Chemother. 2012;67:494-502.

Bainbridge C, Dahlin LB, Szczypa PP, Cappelleri JC, Guérin D, Gerber RA. Current trends in the surgical management of Dupuytren’s disease in Europe: an analysis of patient charts. Eur Orthop Traumatol. 2012;3:31-41.